Why biotech companies face employment claims
Milestone-driven staffing means reductions after trial setbacks — and RIFs of highly credentialed staff generate discrimination claims where selection criteria were built under time pressure.
Equity and bonus disputes at separation are the sector’s signature employment claim: departing scientists challenge vesting treatment, milestone-bonus interpretation, and inventions-assignment scope in the same demand letter.
Beyond EPL: the rest of the management liability picture
Every financing round, data readout, and partnership announcement is a statement investors can later challenge — private-company D&O with the right entity and side-A structure is the board’s baseline. Research data and manufacturing systems raise cyber stakes; a 401(k) adds fiduciary duty. Explore D&O insurance, cyber liability, and fiduciary liability, or start with employment practices liability.
What a claim can look like
After a Phase II miss, a company cuts a third of R&D. Two senior scientists allege the selection spared younger, cheaper staff doing similar work; the hastily built selection matrix becomes the deposition centerpiece.
A down-round’s terms dilute early investors, who allege the board favored the lead insider fund. Individual directors are named; the D&O tower — not the company’s cash — is what stands between them and defense costs.
Scenarios are illustrative composites, not descriptions of actual claims or outcomes. Whether any claim is covered depends on the policy issued.
What carriers will ask about your company
- Headcount by function and any planned reductions
- Cap table complexity — investor classes, insider participation
- Financing history and next-round timeline
- Equity plan administration and separation practices
- Three-year claims history
- Gross annual revenue/funding and payroll
We market your account and you compare terms side by side — no obligation.
Get Multiple Quotes within minutesFrequently asked questions
- We are pre-revenue. Do we really need this now?
- Pre-revenue is when D&O matters most — the company’s value is its statements to investors. Most institutional term sheets require D&O at close.
- What limits do boards typically expect?
- Limits scale with financing stage and cap-table complexity rather than revenue. We benchmark against stage-comparable placements when marketing the account.
- Are RIF-related claims insurable?
- Yes — EPLI answers them, and carriers will ask about selection process. Involving us before a reduction lets coverage and process align.
- Can D&O, EPL, fiduciary, and cyber be packaged?
- For private biotechs, yes — a management liability package marketed together typically prices and coordinates better than separate placements.
Provident Financial Group is an independent insurance agency, not a carrier. We place coverage for biotech companies in New Jersey, New York, Connecticut, Vermont, Ohio, Pennsylvania, Michigan, Kansas, North Carolina, South Carolina, the District of Columbia, Virginia, Maryland, Delaware, Georgia, Florida, Texas, California, Kentucky, Massachusetts, Indiana, Nevada, and Arizona.